Corcept Therapeutics (CORT) EBT Margin (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of EBT Margin data on file, last reported at 27.12% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin fell 3323.0% year-over-year to 27.12%; the trailing twelve-month figure through Mar 2026 stood at 1.58% (down 1828.0% YoY), and the FY2025 full-year result was 8.73%, down 1519.0% from the prior year.
• EBT Margin retreated to 27.12% in Q1 2026, from 4.9% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 32.44% in Q3 2022 to a low of 27.12% in Q1 2026.
• A 5-year average of 18.89% and a median of 23.84% in 2024 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin surged 639 bps in 2024 and slumped 3323 bps in 2026, its largest moves.
• Tracing CORT's EBT Margin over 5 years: stood at 23.56% in 2022, then climbed by 15 bps to 27.18% in 2023, then plunged by 35 bps to 17.57% in 2024, then slumped by 72 bps to 4.9% in 2025, then sank by 653 bps to 27.12% in 2026.
• Business Quant data shows CORT's EBT Margin at 27.12% in Q1 2026, 4.9% in Q4 2025, and 7.34% in Q3 2025.